Research programme: therapeutic peptides - Compugen

Drug Profile

Research programme: therapeutic peptides - Compugen

Alternative Names: CGEN-241; CGEN-25007; CGEN-25008; CGEN-34; CGEN-40; DAC Blockers

Latest Information Update: 27 Jan 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Compugen
  • Class Peptides
  • Mechanism of Action Angiopoietin inhibitors; Atrial peptide agonists; Clusterin inhibitors; Heat-shock protein inhibitors; Hepatocyte growth factor inhibitors; Immunosuppressants; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation
  • No development reported Cardiovascular disorders; Renal failure

Most Recent Events

  • 27 Jan 2012 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 27 Jan 2012 No development reported - Preclinical for Renal failure in USA (unspecified route)
  • 24 Jun 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top